Nektar Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
Rhea-AI Summary
Nektar Therapeutics (NKTR) reported Q4 and full year 2024 financial results. The company ended 2024 with $269.1 million in cash and investments, down from $329.4 million in 2023. Q4 2024 revenue increased to $29.2 million from $23.9 million year-over-year, while full-year revenue rose to $98.4 million from $90.1 million.
The company reported Q4 2024 net income of $7.3 million ($0.03 per share), compared to a net loss of $42.1 million in Q4 2023. Full-year 2024 net loss was $119.0 million ($0.58 per share), improved from $276.1 million in 2023. Operating expenses decreased significantly to $203.6 million in 2024 from $353.8 million in 2023, partly due to a $40.4 million gain from the Huntsville facility sale.
Key developments include completed enrollment in Phase 2b trials for rezpegaldesleukin in atopic dermatitis and alopecia areata, with topline data expected in Q2 and Q4 2025. The company also sold its Huntsville manufacturing business to Ampersand Capital Partners for $90 million in enterprise value.
Positive
- Revenue increased 9.2% to $98.4 million in 2024
- Operating expenses decreased 42.5% to $203.6 million in 2024
- Net loss improved significantly from $276.1M in 2023 to $119.0M in 2024
- $40.4 million gain from Huntsville facility sale
- FDA Fast Track designation received for rezpegaldesleukin
Negative
- Cash position decreased by $60.3 million from 2023 to $269.1 million
- Continued net loss of $119.0 million in 2024
- R&D expenses increased to $120.9 million from $114.2 million in 2023
News Market Reaction 1 Alert
On the day this news was published, NKTR declined 0.56%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Cash and investments in marketable securities on December 31, 2024 were
"The significant progress we made last year in advancing our immunology pipeline positions us for two value-creating data milestones in 2025," said Howard W. Robin, President and CEO of Nektar. "With enrollment now complete for the atopic dermatitis and alopecia areata Phase 2b trials, we are on track to report topline data for rezpegaldesleukin in the second quarter and in the fourth quarter of this year, respectively. This program is poised to emerge as the first T regulatory cell treatment option to help the millions of patients battling these chronic autoimmune disorders."
"We also made progress on our preclinical immunology programs," continued Robin. "We reported the first data for NKTR-0165, our novel antibody targeting TNFR2, and unveiled a new bispecific antibody, NKTR-0166. We plan to submit the IND for NKTR-0165 in the second half of this year."
Summary of Financial Results
Revenue in the fourth quarter of 2024 was
Total operating costs and expenses in the fourth quarter of 2024 were
R&D expense in the fourth quarter of 2024 was
G&A expense was
Restructuring and impairment costs were
Net income for the fourth quarter of 2024 was
2024 and Recent Business Highlights
- In February 2025, Nektar announced completion of target enrollment in the REZOLVE-AA 84-patient Phase 2b clinical trial of rezpegaldesleukin in severe-to-very severe alopecia areata.
- In February 2025, Nektar announced a new clinical trial agreement with TrialNet, an international clinical trial network at the forefront of diabetes research, to evaluate rezpegaldesleukin in a 66-patient Phase 2 study with new onset type 1 diabetes mellitus.
- In February 2025, the FDA granted Fast Track designation for rezpegaldesleukin for the treatment of adult and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.
- In January 2025, Nektar announced completion of target enrollment in the REZOLVE-AD 396-patient Phase 2b clinical trial of rezpegaldesleukin in moderate-to-severe atopic dermatitis.
- At the 66th Annual ASH Meeting in December 2024, Nektar presented proof-of-concept clinical data showing that NKTR-255 following CD19-directed CAR-T therapy enhanced complete response rates in patients with relapsed or refractory large B-cell lymphoma, with
73% of the NKTR-255 treatment group, compared to50% of the placebo group, achieving a complete response at 6 months. - At the 2024 American College of Rheumatology (ACR) Convergence meeting in November 2024, Nektar presented first preclinical data from its novel CSF-1 Program, NKTR-422. The program demonstrated inflammation resolution and tissue repair in multiple preclinical models of chronic inflammatory conditions.
- At the Society for Immunotherapy of Cancer (SITC) Annual Meeting in November 2024, Nektar and collaborators presented results from a planned interim analysis in the Phase 2 trial of NKTR-255 for the treatment of patients with radiation induced lymphopenia in locally advanced non-small cell lung cancer. These results suggest that NKTR-255 effectively reversed radiation induced lymphopenia in patients with locally advanced NSCLC receiving consolidation therapy with durvalumab. The Phase 2 single-arm study is being conducted by MD Anderson.
- In November 2024, Nektar announced a definitive agreement with Ampersand Capital Partners to sell its commercial PEGylation manufacturing business in
Huntsville, Alabama for$90 million $70 million $20 million - In October 2024, Nature Communications published results from Phase 1b studies of rezpegaldesleukin in patients with moderate-to-severe atopic dermatitis or chronic plaque psoriasis. Data from both trials demonstrate durable dose-dependent improvements in physician-assessed disease activity and patient-reported outcomes. In the atopic dermatitis study, EASI improvement of ≥
75% and vIGA-AD responses were maintained for 36 weeks after treatment discontinuation in71% and80% of week 12 responders. Biomarker analyses demonstrate plurality of Treg-mediated pathways with potential effect on tissue resident memory T cell populations resulting in sustained efficacy seen in the antigen challenged mouse model and in clinical trials. - In October 2024, Nektar announced publication in Blood of Phase 1 data showing that NKTR-255 in Combination with Autologous CD19-22 CAR-T cell therapy in patients with B-cell acute lymphoblastic leukemia exhibited relapse-free/progression-free survival for
67% of patients at 12 months, double that of historical controls. Eight of nine patients achieved complete remission, all without detectable measurable residual disease. - At the European Alliance of Associations for Rheumatology (EULAR) in June 2024, Nektar presented preclinical data on NKTR-0165, a TNFR2 agonist antibody, demonstrating selective enhancement of Treg cell function through novel agonistic mechanism. IND-enabling studies are underway for NKTR-0165 with first-in-human studies planned in first half of 2025.
Conference Call to Discuss Fourth Quarter 2024 Financial Results
Nektar management will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time on March 12, 2025.
This press release and live audio-only webcast of the conference call can be accessed through a link that is posted on the Home Page and Investors section of the Nektar website: http://ir.nektar.com/. The web broadcast of the conference call will be available for replay through April 12, 2025.
To access the conference call, please pre-register at Nektar Earnings Call Registration. All registrants will receive dial-in information and a PIN allowing them to access the live call.
About Nektar Therapeutics
Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar's lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in two Phase 2b clinical trials, one in atopic dermatitis and one in alopecia areata. Nektar's pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. Nektar, together with various partners, is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials. Nektar is headquartered in San Francisco,
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements which can be identified by words such as: "will," "expect," "develop," "potential," "advance," "plan," and similar references to future periods. Examples of forward-looking statements include, among others, statements regarding the therapeutic potential of, and future development plans for, rezpegaldesleukin, NKTR-0165, NKTR-0166, NKTR-422, and NKTR-255. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results to differ materially from those indicated in the forward-looking statements include, among others: (i) our statements regarding the therapeutic potential of rezpegaldesleukin, NKTR-0165, NKTR-0166, NKTR-422 and NKTR-255 are based on preclinical and clinical findings and observations and are subject to change as research and development continue; (ii) rezpegaldesleukin, NKTR-0165, NKTR-0166, NKTR-422 and NKTR-255 are investigational agents and continued research and development for these drug candidates is subject to substantial risks, including negative safety and efficacy findings in future clinical studies (notwithstanding positive findings in earlier preclinical and clinical studies); (iii) rezpegaldesleukin, NKTR-0165, NKTR-0166, NKTR-422 and NKTR-255 are in clinical development and the risk of failure is high and can unexpectedly occur at any stage prior to regulatory approval; (iv) the timing of the commencement or end of clinical trials and the availability of clinical data may be delayed or unsuccessful due to regulatory delays, slower than anticipated patient enrollment, manufacturing challenges, changing standards of care, evolving regulatory requirements, clinical trial design, clinical outcomes, competitive factors, or delay or failure in ultimately obtaining regulatory approval in one or more important markets; (v) a Fast Track designation does not increase the likelihood that rezpegaldesleukin will receive marketing approval in the United States; (vi) patents may not issue from our patent applications for our drug candidates, patents that have issued may not be enforceable, or additional intellectual property licenses from third parties may be required; and (vii) certain other important risks and uncertainties set forth in our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 8, 2024. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
For Investors:
Vivian Wu of Nektar Therapeutics
628-895-0661
For Media:
Madelin Hawtin
LifeSci Communications
603-714-2638
mhawtin@lifescicomms.com
NEKTAR THERAPEUTICS | ||||||||||
CONDENSED CONSOLIDATED BALANCE SHEETS | ||||||||||
(In thousands) | ||||||||||
(Unaudited) | ||||||||||
ASSETS | December 31, 2024 | December 31, 2023(1) | ||||||||
Current assets: | ||||||||||
Cash and cash equivalents | $ 44,252 | $ 35,277 | ||||||||
Short-term investments | 210,974 | 268,339 | ||||||||
Accounts receivable | - | 1,205 | ||||||||
Inventory, net | - | 16,101 | ||||||||
Other current assets | 6,066 | 9,779 | ||||||||
Total current assets | 261,292 | 330,701 | ||||||||
Long-term investments | 13,869 | 25,825 | ||||||||
Property, plant and equipment, net | 3,411 | 18,856 | ||||||||
Operating lease right-of-use assets | 8,413 | 18,007 | ||||||||
Equity method investment in Gannet BioChem | 12,218 | - | ||||||||
Other assets | 4,647 | 4,644 | ||||||||
Total assets | $ 303,850 | $ 398,033 | ||||||||
LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||||
Current liabilities: | ||||||||||
Accounts payable | 11,560 | 9,848 | ||||||||
Accrued expenses | 29,972 | 22,162 | ||||||||
Operating lease liabilities, current portion | 19,868 | 19,259 | ||||||||
Total current liabilities | 61,400 | 51,269 | ||||||||
Operating lease liabilities, less current portion | 82,696 | 98,517 | ||||||||
Liabilities related to the sales of future royalties, net | 91,776 | 112,625 | ||||||||
Other long-term liabilities | 7,241 | 4,635 | ||||||||
Total liabilities | 243,113 | 267,046 | ||||||||
Commitments and contingencies | ||||||||||
Stockholders' equity: | ||||||||||
Preferred stock | - | - | ||||||||
Common stock | 19 | 19 | ||||||||
Capital in excess of par value | 3,659,867 | 3,608,137 | ||||||||
Treasury stock | (3,000) | - | ||||||||
Accumulated other comprehensive income (loss) | 61 | 80 | ||||||||
Accumulated deficit | (3,596,210) | (3,477,249) | ||||||||
Total stockholders' equity | 60,737 | 130,987 | ||||||||
Total liabilities and stockholders' equity | $ 303,850 | $ 398,033 | ||||||||
(1) The consolidated balance sheet at December 31, 2023 has been derived from the audited financial statements at that date but does not include all | ||||||||||
of the information and notes required by generally accepted accounting principles in | ||||||||||
NEKTAR THERAPEUTICS | ||||||||||||||
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | ||||||||||||||
(In thousands, except per share information) | ||||||||||||||
(Unaudited) | ||||||||||||||
Three months ended December 31, | Year ended December 31, | |||||||||||||
2024 | 2023 | 2024 | 2023 | |||||||||||
Revenue: | ||||||||||||||
Product sales | $ 12,874 | $ 5,483 | $ 33,563 | $ 20,681 | ||||||||||
Non-cash royalty revenue related to the sales of future royalties | 16,238 | 18,061 | 64,267 | 68,921 | ||||||||||
License, collaboration and other revenue | 63 | 341 | 597 | 520 | ||||||||||
Total revenue | 29,175 | 23,885 | 98,427 | 90,122 | ||||||||||
Operating costs and expenses: | ||||||||||||||
Cost of goods sold | 7,978 | 7,283 | 30,686 | 33,768 | ||||||||||
Research and development | 28,744 | 29,942 | 120,908 | 114,162 | ||||||||||
General and administrative | 17,135 | 17,320 | 76,751 | 77,417 | ||||||||||
Restructuring and impairment | 1,360 | 2,851 | 15,670 | 51,958 | ||||||||||
Impairment of goodwill | - | - | - | 76,501 | ||||||||||
Gain on sale of the | (40,390) | - | (40,390) | - | ||||||||||
Total operating costs and expenses | 14,827 | 57,396 | 203,625 | 353,806 | ||||||||||
Income/(Loss) from operations | 14,348 | (33,511) | (105,198) | (263,684) | ||||||||||
Non-operating income (expense): | ||||||||||||||
Non-cash interest expense on liabilities related to the sales of future royalties | (10,153) | (6,867) | (28,112) | (25,334) | ||||||||||
Interest income | 2,942 | 4,617 | 14,500 | 19,009 | ||||||||||
Other income (expense), net | (135) | (6,347) | (390) | (6,247) | ||||||||||
Total non-operating income (expense), net | (7,346) | (8,597) | (14,002) | (12,572) | ||||||||||
Income/(Loss) before provision for income taxes | 7,002 | (42,108) | (119,200) | (276,256) | ||||||||||
Provision (benefit) for income taxes | (259) | (29) | (239) | (200) | ||||||||||
Net Income/(loss) | $ 7,261 | $ (42,079) | $ (118,961) | $ (276,056) | ||||||||||
Basic and diluted net income/(loss) per share | $ 0.03 | $ (0.22) | $ (0.58) | $ (1.45) | ||||||||||
Weighted average shares outstanding used in computing net income/(loss) per share | ||||||||||||||
Basic | 209,737 | 191,040 | 205,661 | 190,001 | ||||||||||
Diluted | 213,594 | 191,040 | 205,661 | 190,001 | ||||||||||
View original content to download multimedia:https://www.prnewswire.com/news-releases/nektar-therapeutics-reports-fourth-quarter-and-full-year-2024-financial-results-302400327.html
SOURCE Nektar Therapeutics
FAQ
What were Nektar Therapeutics (NKTR) Q4 2024 financial results?
When will NKTR report rezpegaldesleukin trial results in 2025?
How much did Nektar receive for selling its Huntsville manufacturing facility?
How long will NKTR's current cash position support operations?
What was NKTR's full-year 2024 revenue and net loss?
